Skip to main content
profile image
Selected Works of Pearl Kwong, MD, PhD, FAAD
Article
Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum.
American Journal of Clinical Dermatology (2021)
  • Lawrence F. Eichenfield, University of California, San Diego
  • Elaine Siegfried, Saint Louis University
  • Pearl Kwong, Solutions Through Advanced Research, Jacksonville, FL, USA.
  • Mark McBride, Instat Consulting, Inc., Chatham, NJ, USA.
  • Jayson Rieger, Verrica Pharmaceuticals Inc., West Chester, PA, USA.
  • David Glover, Verrica Pharmaceuticals Inc., West Chester, PA, USA.
  • Cynthia Willson, Verrica Pharmaceuticals Inc., West Chester, PA, USA.
  • Matthew Davidson, Verrica Pharmaceuticals Inc., West Chester, PA, USA.
  • Patrick Burnett, Verrica Pharmaceuticals Inc., West Chester, PA, USA.
  • Melissa Olivadoti, Verrica Pharmaceuticals Inc., West Chester, USA
Link
Disciplines
Publication Date
February 18, 2021
DOI
10.1007/S40257-020-00570-8
Citation Information
Lawrence F. Eichenfield, Elaine Siegfried, Pearl Kwong, Mark McBride, et al.. "Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum." American Journal of Clinical Dermatology Vol. 22 Iss. 2 (2021) p. 257 - 265
Available at: http://works.bepress.com/pearl-kwong/3/